<DOC>
	<DOCNO>NCT01088243</DOCNO>
	<brief_summary>The purpose study understand drug call mesalamine help control inflammation associate chronic beryllium disease ( CBD ) . We hypothesize CBD subject treat prednisone , mesalamine treatment enhance immunosuppressive effect prednisone , thus reduce immune response beryllium .</brief_summary>
	<brief_title>Targeting Oxidative Stress Chronic Beryllium Disease</brief_title>
	<detailed_description>The overall goal study understand role oxidative stress potential therapeutic target pathogenesis chronic beryllium disease ( CBD ) . CBD inflammatory hypersensitivity lung disease occur estimate 800,000 beryllium-exposed worker United Sates . CBD characterize presence pulmonary non-caseating granuloma accumulation macrophage beryllium specific CD4+ T cell ( Newman et al . 1998 ) . Upon beryllium stimulation vitro , beryllium specific CD4+ T cell proliferate produce Th1 cytokine ( i.e . TNF-α , IFN-γ , IL-2 ) unusually high level ( Tinkle et al . 1997 ) . The molecular mechanism ( ) beryllium regulate chronic production cytokine unknown . Exciting preliminary study indicate beryllium alters redox status T cell may adversely modulate immune response CBD . Based point , novel hypothesis propose : 1 ) oxidative stress enhances T cell response antigen enhancement may explain excessive cytokine response pathogenesis pulmonary granuloma CBD ; 2 ) inherent difference T cell antioxidant status critical factor pathogenesis CBD . This proposal pilot clinical trial examine approve drug treatment ulcerative colitis ( 5-amino salicylic acid , 5-ASA ) , anti-inflammatory antioxidant property , potential new approach CBD treatment . In clinical trial , 40 CBD subject already treat prednisone , treat either placebo 5-ASA determine effect beryllium stimulate immune response lung undergo bronchoscopy bronchoalveolar lavage blood undergoing venipuncture 6 week treatment 5-ASA . As secondary outcome , also assess subject clinical response short course 5-ASA use spirometry . Bronchoscopies optional . Patients option participate undergoing venipuncture lung function test .</detailed_description>
	<mesh_term>Berylliosis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Diagnosis chronic beryllium disease base criterion : 1 . History beryllium exposure , ; 2 . Positive blood and/or bronchoalveolar lavage Beryllium Lymphocyte Proliferation Tests ( BeLPT ) , ; 3 . Biopsyproven pathologic change consistent CBDnoncaseating granuloma and/or mononuclear cell interstitial infiltrates , ; 4 . Positive bronchoalveolar lavage ( BAL ) BeLPT &gt; 15 % lymphocytes BAL fluid . History Hepatic disease History Renal disease Hypersensitivity Pentasa ( 5ASA ) salicylate . Pregnancy Presence another disease may expect significantly affect patient mortality ( e.g. , HIV ) , severe cor pulmonale ) ; The use blood thinner . Current use tobacco ( smoke otherwise ) past 6 month Patient inability participate study , inability undergo venipuncture BAL procedure ( undergo bronchoscopy ) form part inclusion/exclusion criterion part outcome measure . If undergoing bronchoscopy : Severe room air hypoxemia ( preclude transbronchial lung biopsy and/or BAL ) , e.g. , pO2 &lt; 45 ( Denver altitude 5,280 foot ) ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Berylliosis</keyword>
	<keyword>Beryllium Disease</keyword>
</DOC>